COMBINATION CHEMOTHERAPY HAS BEEN USED AS INTENSIVE THERAPY FOR HIGH-RISK AML IN ADULTS FOR DECADES1,2*

combination-desk-en
combination-desk-en-mob

In the early 2000s,  
VYXEOS began development in Canada – a liposomal formulation designed to optimize the synergistic ratio of daunorubicin and cytarabine.1

VYXEOS OFFERS AN INTENSIVE TREATMENT TO HIGH-RISK ADULT PATIENTS WITH sAML WHO, UP UNTIL NOW, HAD FEW OPTIONS AVAILABLE TO THEM.4*‡

*High-risk AML defined as t-AML or AML-MRC.

†Conventional chemotherapy includes the 7+3/5+2 regimen for induction and consolidation, using cytarabine and daunorubicin.3

‡sAML defined as AML occurring after therapy and/or an antecedent myeloid disease e.g. MDS or MPN, excluding chronic myeloid leukemia, regardless of prior cytotoxic therapy for these disorders. This includes the subtypes, t-AML, AML-MRC and CMMoL AML.5,6

References: 1. Tolcher AW, Mayer LD. Improving combination cancer therapy: the CombiPlex® development platform. Future Oncol 2018;14:1317–1332. 2. Tardi P, Johnstone S, Harasym N, et al. In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. Leuk Res 2009;33:129–39. 3. Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol 2018;36:2684–2692. 4. Talati C, Lancet JE. CPX-351: changing the landscape of treatment for patients with secondary acute myeloid leukemia. Future Oncol 2018;14:1147–1154. 5. Granfeldt Østgård LS, Medeiros BC, Sengeløv H, et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: A national population-based cohort study. J Clin Oncol 2015;33:3641–9. 6. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Myeloid Leukemia V.2.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed March 2021. To view the most recent and complete version of the guideline, go online to NCCN.org.

CA-VYX-2400007-E | March 2024.